A phase 1b/2 trial published in Nature Medicine reports that first-line treatment with trastuzumab plus nivolumab, gemcitabine, and cisplatin produced encouraging clinical response rates in patients with HER2-positive unresectable biliary tract cancer, with HER2 expression linke…
Trastuzumab and Nivolumab Combo Shows Encouraging Response in HER2-Positive Biliary Tract Cancer
A phase 1b/2 trial published in Nature Medicine reports that first-line treatment with trastuzumab plus nivolumab, gemcitabine, and cisplatin produced encouraging clinical response rates in patients with HER2-positive unresectable biliary tract cancer, with HER2 expression linked to clinical benefit.
Gallbladder cancer · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.